AU2014338612C1 - Pharmaceutical compositions comprising antibacterial agents - Google Patents
Pharmaceutical compositions comprising antibacterial agents Download PDFInfo
- Publication number
- AU2014338612C1 AU2014338612C1 AU2014338612A AU2014338612A AU2014338612C1 AU 2014338612 C1 AU2014338612 C1 AU 2014338612C1 AU 2014338612 A AU2014338612 A AU 2014338612A AU 2014338612 A AU2014338612 A AU 2014338612A AU 2014338612 C1 AU2014338612 C1 AU 2014338612C1
- Authority
- AU
- Australia
- Prior art keywords
- pharmaceutically acceptable
- formula
- compound
- cefepime
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3309/MUM/2013 | 2013-10-22 | ||
| PCT/IB2014/065522 WO2015059643A1 (en) | 2013-10-22 | 2014-10-22 | Pharmaceutical compositions comprising antibacterial agents |
| IN3309MU2013 IN2013MU03309A (enExample) | 2013-10-22 | 2014-10-22 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2014338612A1 AU2014338612A1 (en) | 2016-05-12 |
| AU2014338612B2 AU2014338612B2 (en) | 2019-12-19 |
| AU2014338612C1 true AU2014338612C1 (en) | 2020-09-24 |
Family
ID=52003012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2014338612A Active AU2014338612C1 (en) | 2013-10-22 | 2014-10-22 | Pharmaceutical compositions comprising antibacterial agents |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9827235B2 (enExample) |
| EP (1) | EP3060213B1 (enExample) |
| JP (2) | JP2016538258A (enExample) |
| KR (1) | KR102340010B1 (enExample) |
| CN (2) | CN106102741A (enExample) |
| AU (1) | AU2014338612C1 (enExample) |
| BR (1) | BR112016008979B1 (enExample) |
| CA (1) | CA2928364C (enExample) |
| DK (1) | DK3060213T3 (enExample) |
| ES (1) | ES2902456T3 (enExample) |
| HU (1) | HUE057504T2 (enExample) |
| IN (1) | IN2013MU03309A (enExample) |
| MX (1) | MX375934B (enExample) |
| NZ (1) | NZ719215A (enExample) |
| PL (1) | PL3060213T3 (enExample) |
| PT (1) | PT3060213T (enExample) |
| RU (1) | RU2702361C2 (enExample) |
| WO (1) | WO2015059643A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107580595B (zh) * | 2015-05-07 | 2020-09-18 | 拜欧蒂姆公司 | 杂环化合物及它们在预防或治疗细菌感染中的应用 |
| CN109310682A (zh) * | 2016-06-17 | 2019-02-05 | 沃克哈特有限公司 | 抗菌组合物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013030733A1 (en) * | 2011-08-27 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections |
| US20130225554A1 (en) * | 2011-12-02 | 2013-08-29 | Naeja Pharmaceutical Inc. | New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
| WO2014108872A1 (en) * | 2013-01-14 | 2014-07-17 | Wockhardt Limited | Compositions and methods for treating bacterial infections |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465428B1 (en) * | 1999-08-27 | 2002-10-15 | Aventis Pharma S.A. | Pharmaceutical combinations based on dalfopristine and quinupristine, and on cefepime |
| MX2007007235A (es) * | 2004-12-17 | 2007-10-19 | Venus Remedies Ltd | Combinacion de antibioticos para proporcionar una solucion total al tratamiento de infecciones. |
| RU2366450C1 (ru) * | 2008-08-04 | 2009-09-10 | Валентина Васильевна Малиновская | Средство для лечения тяжелых инфекционных заболеваний и смешанных инфекций |
| CA2842777C (en) * | 2011-07-26 | 2015-12-29 | Wockhardt Limited | Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor |
| HUE046893T2 (hu) * | 2012-05-30 | 2020-04-28 | Meiji Seika Pharma Co Ltd | Új ß-laktamáz inhibitor és eljárás elõállítására |
-
2014
- 2014-10-22 WO PCT/IB2014/065522 patent/WO2015059643A1/en not_active Ceased
- 2014-10-22 KR KR1020167013330A patent/KR102340010B1/ko active Active
- 2014-10-22 DK DK14806074.2T patent/DK3060213T3/da active
- 2014-10-22 BR BR112016008979-0A patent/BR112016008979B1/pt active IP Right Grant
- 2014-10-22 US US15/030,526 patent/US9827235B2/en active Active - Reinstated
- 2014-10-22 AU AU2014338612A patent/AU2014338612C1/en active Active
- 2014-10-22 JP JP2016525054A patent/JP2016538258A/ja active Pending
- 2014-10-22 PL PL14806074T patent/PL3060213T3/pl unknown
- 2014-10-22 NZ NZ719215A patent/NZ719215A/en not_active IP Right Cessation
- 2014-10-22 CN CN201480069915.6A patent/CN106102741A/zh active Pending
- 2014-10-22 ES ES14806074T patent/ES2902456T3/es active Active
- 2014-10-22 HU HUE14806074A patent/HUE057504T2/hu unknown
- 2014-10-22 RU RU2016115376A patent/RU2702361C2/ru active
- 2014-10-22 CA CA2928364A patent/CA2928364C/en active Active
- 2014-10-22 CN CN202110966872.3A patent/CN113577084A/zh active Pending
- 2014-10-22 IN IN3309MU2013 patent/IN2013MU03309A/en unknown
- 2014-10-22 MX MX2016005161A patent/MX375934B/es active IP Right Grant
- 2014-10-22 PT PT148060742T patent/PT3060213T/pt unknown
- 2014-10-22 EP EP14806074.2A patent/EP3060213B1/en active Active
-
2019
- 2019-04-25 JP JP2019083866A patent/JP6886996B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013030733A1 (en) * | 2011-08-27 | 2013-03-07 | Wockhardt Limited | 1,6- diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections |
| US20130225554A1 (en) * | 2011-12-02 | 2013-08-29 | Naeja Pharmaceutical Inc. | New bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
| WO2014108872A1 (en) * | 2013-01-14 | 2014-07-17 | Wockhardt Limited | Compositions and methods for treating bacterial infections |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113577084A (zh) | 2021-11-02 |
| IN2013MU03309A (enExample) | 2015-07-17 |
| AU2014338612B2 (en) | 2019-12-19 |
| PL3060213T3 (pl) | 2022-02-14 |
| US20160303104A1 (en) | 2016-10-20 |
| KR20160072254A (ko) | 2016-06-22 |
| DK3060213T3 (da) | 2022-01-03 |
| WO2015059643A1 (en) | 2015-04-30 |
| RU2016115376A (ru) | 2017-11-28 |
| NZ719215A (en) | 2020-04-24 |
| KR102340010B1 (ko) | 2021-12-16 |
| PT3060213T (pt) | 2021-12-24 |
| CA2928364A1 (en) | 2015-04-30 |
| MX375934B (es) | 2025-03-07 |
| ES2902456T3 (es) | 2022-03-28 |
| RU2702361C2 (ru) | 2019-10-08 |
| CA2928364C (en) | 2021-11-23 |
| CN106102741A (zh) | 2016-11-09 |
| RU2016115376A3 (enExample) | 2018-07-02 |
| US9827235B2 (en) | 2017-11-28 |
| JP2019116508A (ja) | 2019-07-18 |
| HUE057504T2 (hu) | 2022-05-28 |
| BR112016008979A2 (enExample) | 2017-08-01 |
| MX2016005161A (es) | 2016-10-05 |
| EP3060213A1 (en) | 2016-08-31 |
| JP2016538258A (ja) | 2016-12-08 |
| BR112016008979B1 (pt) | 2023-04-25 |
| EP3060213B1 (en) | 2021-10-13 |
| JP6886996B2 (ja) | 2021-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20180243274A1 (en) | Antibacterial compositions | |
| US9789097B2 (en) | Pharmaceutical compositions comprising antibacterial agents | |
| CA2928364C (en) | Pharmaceutical compositions comprising antibacterial agents | |
| WO2015136387A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
| EP3107539A1 (en) | Pharmaceutical combinations comprising antibacterial agents | |
| AU2014343327A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
| AU2014338612A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
| WO2015159167A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
| WO2015063714A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
| WO2015150926A1 (en) | Pharmaceutical compositions comprising cefepime or sulbactam | |
| CA2954553C (en) | Pharmaceutical compositions comprising antibacterial agents | |
| WO2015159263A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
| WO2018193368A1 (en) | Antibacterial compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 APR 2020 |
|
| TH | Corrigenda |
Free format text: IN VOL 34 , NO 26 , PAGE(S) 3577 UNDER THE HEADING AMENDMENTS - APPLICATION FOR AMENDMENTS UNDER THE NAME WOCKHARDT LIMITED, APPLICATION NO. 2014338612 CORRECT THE DATE OF THE STATEMENTS FILED TO READ 15 APR 2020 AND 10 JUN 2020 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENTS FILED 15 APR 2020 AND 10 JUNE 2020 |
|
| FGA | Letters patent sealed or granted (standard patent) |